UNSPSC 51352415: Ethinyl estradiol/norethindrone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352415 Ethinyl estradiol/norethindrone, a Commodity code, encompasses state and local government procurement of this specific oral contraceptive pharmaceutical product through cooperative purchasing vehicles and direct state agency pharmacy benefit programs. Recent state and local solicitations show demand for the drug sourced through multiple channels: cooperative purchasing agreements requiring supply through authorized wholesalers with detailed NDC and SKU documentation, and emerging direct-to-manufacturer contracting models designed to bypass traditional pharmacy benefit managers and group purchasing organizations. State health and human services agencies and multistate cooperative purchasing alliances are the primary issuing bodies, alongside participating state and local government facilities that receive pharmaceuticals through cooperative agreements. The work involves manufacturers and distributors certifying compliance with cGMP and Drug Supply Chain Security Act requirements, maintaining relationships with authorized wholesalers, and submitting comprehensive pricing and product data in standardized formats with flexible pricing structures such as net pricing, WAC-minus, or flat pricing models.

Recent activity appears concentrated in the Upper Midwest and Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; the contract term begins July 1, 2026 for awarded vendors supplying through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 with a response deadline of April 3, 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's interest in reshaping pharmacy benefit contracting before issuing a formal RFP. Neither solicitation disclosed specific award values or budget ranges; the MMCAP RFP applies a 3 percent administrative fee on purchases and performance penalties for contract violations.